BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 28677067)

  • 1. Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model.
    Do Minh D; Chapiro J; Gorodetski B; Huang Q; Liu C; Smolka S; Savic LJ; Wainstejn D; Lin M; Schlachter T; Gebauer B; Geschwind JF
    Eur Radiol; 2017 Dec; 27(12):4995-5005. PubMed ID: 28677067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: A single-center propensity score matching analysis.
    Shi Q; Liu J; Li T; Zhou C; Wang Y; Huang S; Yang C; Chen Y; Xiong B
    Clin Res Hepatol Gastroenterol; 2022 May; 46(5):101893. PubMed ID: 35247625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conventional versus drug-eluting beads chemoembolization for infiltrative hepatocellular carcinoma: a comparison of efficacy and safety.
    Zhang ZS; Li HZ; Ma C; Xiao YD
    BMC Cancer; 2019 Nov; 19(1):1162. PubMed ID: 31783814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma.
    Kang YJ; Lee BC; Kim JK; Yim NY; Kim HO; Cho SB; Jeong YY
    Cardiovasc Intervent Radiol; 2020 Jan; 43(1):55-64. PubMed ID: 31646378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intra-arterial therapies for unresectable and chemorefractory colorectal cancer liver metastases: a systematic review and meta-analysis.
    Levy J; Zuckerman J; Garfinkle R; Acuna SA; Touchette J; Vanounou T; Pelletier JS
    HPB (Oxford); 2018 Oct; 20(10):905-915. PubMed ID: 29887263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization.
    Gorodetski B; Chapiro J; Schernthaner R; Duran R; Lin M; Lee H; Lenis D; Stuart EA; Nonyane BA; Pekurovsky V; Tamrazi A; Gebauer B; Schlachter T; Pawlik TM; Geschwind JF
    Eur Radiol; 2017 Feb; 27(2):526-535. PubMed ID: 27277261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transarterial chemoembolisation and radioembolisation for the treatment of primary liver cancer and secondary liver cancer: a review of the literature.
    Bester L; Meteling B; Boshell D; Chua TC; Morris DL
    J Med Imaging Radiat Oncol; 2014; 58(3):341-52. PubMed ID: 24589204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
    Liu YS; Lin CY; Chuang MT; Lin CY; Tsai YS; Wang CK; Ou MC
    BMC Gastroenterol; 2018 Aug; 18(1):124. PubMed ID: 30075752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Callispheres® drug-eluting beads transarterial chemoembolization might be an efficient and safety down-staging therapy in unresectable liver cancer patients.
    Peng N; Mao L; Tao Y; Xiao K; Yuan G; He S
    World J Surg Oncol; 2022 Aug; 20(1):254. PubMed ID: 35941634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus
    Ludwig JM; Zhang D; Xing M; Kim HS
    Eur Radiol; 2017 May; 27(5):2031-2041. PubMed ID: 27562480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study.
    Wu B; Zhou J; Ling G; Zhu D; Long Q
    World J Surg Oncol; 2018 Mar; 16(1):69. PubMed ID: 29587773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CalliSpheres® drug-eluting beads (DEB) transarterial chemoembolization (TACE) is equally efficient and safe in liver cancer patients with different times of previous conventional TACE treatments: a result from CTILC study.
    Zhang X; Zhou J; Zhu DD; Huang J; Sun JH; Li TF; Shi CS; Sun ZC; Hou QM; Peng ZY; Yu WQ; Ji JS; Gu WJ; Zhou GH; Xie XX; Guo XH; Cao GH; Yu ZH; Xu HH; Fang J; Ying SH; Hu WH; Ji WB; Han J; Wu X; Zheng JP; Luo J; Chen YT; Hu TY; Li L; Hu HJ; Du HJ; Shao GL
    Clin Transl Oncol; 2019 Feb; 21(2):167-177. PubMed ID: 30003530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting.
    Karalli A; Teiler J; Haji M; Seth E; Brismar TB; Wahlin S; Axelsson R; Stål P
    Scand J Gastroenterol; 2019 Jul; 54(7):905-912. PubMed ID: 31287338
    [No Abstract]   [Full Text] [Related]  

  • 14. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma.
    Kloeckner R; Weinmann A; Prinz F; Pinto dos Santos D; Ruckes C; Dueber C; Pitton MB
    BMC Cancer; 2015 Jun; 15():465. PubMed ID: 26059447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver and biliary damages following transarterial chemoembolization of hepatocellular carcinoma: comparison between drug-eluting beads and lipiodol emulsion.
    Monier A; Guiu B; Duran R; Aho S; Bize P; Deltenre P; Dunet V; Denys A
    Eur Radiol; 2017 Apr; 27(4):1431-1439. PubMed ID: 27436016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conventional versus drug-eluting beads chemoembolization for hepatocellular carcinoma: Emphasis on the impact of tumor size.
    Lee YK; Jung KS; Kim DY; Choi JY; Kim BK; Kim SU; Park JY; Ahn SH; Han KH; Kim GM; Kim MD; Park SI; Won JY; Lee DY
    J Gastroenterol Hepatol; 2017 Feb; 32(2):487-496. PubMed ID: 27503585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study.
    Zhang L; Sun JH; Ji JS; Zhong BY; Zhou GH; Song JJ; Hou ZH; Huang P; Zhang S; Li Z; Zhu XL; Ni CF
    AJR Am J Roentgenol; 2021 Oct; 217(4):933-943. PubMed ID: 33245680
    [No Abstract]   [Full Text] [Related]  

  • 18. Drug-eluting bead transarterial chemoembolization (TACE) exhibits superior efficacy and equal tolerance to conventional TACE in hepatocellular carcinoma patients with conventional TACE history.
    Tang J; Huang Z; Xu J; Lv Q; Wang P
    Clin Res Hepatol Gastroenterol; 2022 Mar; 46(3):101814. PubMed ID: 34597848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Supplemental Transarterial Chemoembolization Through Extrahepatic Collateral Arteries with Drug-eluting Beads: Treatment for Unresectable Hepatocellular Carcinoma.
    Chiu SH; Chang PY; Shih YL; Huang WY; Ko KH; Chang WC; Huang GS
    Drug Des Devel Ther; 2020; 14():5029-5041. PubMed ID: 33235441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-eluting beads TACE is safe and non-inferior to conventional TACE in HCC patients with TIPS.
    Fan W; Guo J; Zhu B; Wang S; Yu L; Huang W; Fan H; Li F; Wu Y; Zhao Y; Wang Y; Xue M; Wang H; Li J
    Eur Radiol; 2021 Nov; 31(11):8291-8301. PubMed ID: 33893536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.